Connect your AI

NTHI NTHI Indefinite-Lived Research and Development Assets

Indefinite-Lived Research and Development Assets at other companies

Merck & Co.MRK

$4.13B+35.0%

PfizerPFE

——

Other financials

Income statement

Revenue$40.0K-7.0%

Operating income-$7.1M+77.9%

Net income-$8.8M+72.7%

EPS (diluted)-$0.38+78.7%

Balance sheet

Cash & equivalents$138.6K-97.5%

Total debt$666.1K—

Total equity-$13.2M-37.5%

Total assets$3.3M-60.6%

Cash flow

Operating cash flow-$7.0M-23.7%

CapEx$125.0K—

Free cash flow-$5.2M—

Valuation

Market cap$114.62M+51.0%

Enterprise value$115.15M+51.1%

P/S1,432.9×—

Profitability

Operating margin-46,870.7%—

Net margin-51,613.3%—

FCF margin-26,083.2%—

Returns & leverage

Return on equity338.1%—

Debt / equity-0.1×—

Current ratio0.1×-0.3×

Where this comes from

Reported directly by NTHI in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment.

The official record: NTHI’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →

Ask your AI about NTHI's indefinite-lived research and development assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is NTHI's indefinite-lived research and development assets?: NTHI (NTHI) reported indefinite-lived research and development assets of $1.23M in Q4 2024.
What does indefinite-lived research and development assets mean?: Represents the carrying value of acquired in-process research and development projects that are not yet subject to amortization because they have an indefinite useful life. This metric highlights the company's investment in future innovation and potential pipeline value.